Hasil Pencarian - Hope Qamoos
- Menampilkan 1 - 5 hasil dari 5
-
1
PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS)... oleh Francesca Palandri, Stefanie Gröpper, Michael Loschi, Marcelo Bellesso, Sebastian Grosicki, Pilar Giraldo, Claire Harrison, Tracy Clevenger, Nikki Stuart, Hope Qamoos, Gregory Vosganian, Wayne P. Rothbaum, Srdan Verstovsek, Pankit Vachhani
Diterbitkan 2023-08-01
Artikel -
2
Evaluating Barriers and Opportunities in Delivering High-Quality Oncology Care in a Resource-Limited Setting Using a Comprehensive Needs Assessment Tool oleh Chika R. Nwachukwu, Omobola Mudasiru, Lynn Million, Shruti Sheth, Hope Qamoos, Joseph O. Onah, Anita Okemini, Mojisola Rhodes, Michele Barry, Adekunbiola A. Banjo, Muhameed Habeebu, Tajudeen A. Olasinde, Ami S. Bhatt
Diterbitkan 2018-12-01
Artikel -
3
P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PL... oleh Michael Loschi, Laszlo Rejto, Hun Chuah, Marianna Caramella, Jesus Hernández Rivas, Paolo Sportoletti, Viviane Dubruille, Marcelo Bellesso, Stefanie Gröpper, Carl Crodel, Hope Qamoos, Ashley Socotch, Zhuying Huang, Sarah Wall, Jesse Mcgreivy, Wayne P. Rothbaum, Srdan Verstovsek, Francesca Palandri
Diterbitkan 2023-08-01
Artikel -
4
S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (... oleh Pankit Vachhani, Andrew Perkins, John Mascarenhas, Haifa Kathrin Al-Ali, Jean-Jacques Kiladjian, Sonia Cerquozzi, Jaroslaw Dybko, Regina Garcia Delgado, Jesus Hernández Rivas, Holger Hebart, Zhuying Huang, Cecile Krejsa, Hope Qamoos, Jesse Mcgreivy, Wayne P. Rothbaum, Srdan Verstovsek, Alessandro Vannucchi
Diterbitkan 2023-08-01
Artikel -
5
S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIM... oleh John Mascarenhas, Tania Jain, Salman Otoukesh, Aaron T. Gerds, Alessandro Lucchesi, Iberia Romina Sosa, Kamel Laribi, Elena Mishchenko, Atanas Radinoff, Giulia Benevolo, Alessandro M. Vannucchi, Francoise Boyer, Philippe Quittet, Markus Radsak, Antoine Machet, Prithviraj Bose, Zhuying Huang, Hope Qamoos, Jesse Mcgreivy, Wayne P. Rothbaum, Srdan Verstovsek, Francesco Passamonti
Diterbitkan 2023-08-01
Artikel